Comparison of iLivTouch and FibroScan for the Assessment of Liver Fibrosis and Steatosis in Adult Patients in the US

New Discovery

Status

Enrolling

Conditions

Fatty Liver

Liver Fibrosis

Treatments

Device: FibroScan

Device: iLivTouch

Study type

Observational

Funder types

Other

Industry

Identifiers

NCT06051669

ILT-US-2023-01

Details and patient eligibility

About

This is a multi-center, cross-sectional, and prospective study that will recruit patients from multiple hospitals or outpatient clinics in the USA to the comparison of iLivTouch and FibroScan for the assessment of liver fibrosis and steatosis in adult patients.

Full description

Clinical phase: Phase IV investigator-initiated study Study centers planned: Approximately 4 centers in different regions of the USA

Objectives:

Primary Objectives To evaluate the consistency of Liver Stiffness Measurement (LSM) and Ultrasound/Controlled Attenuation Parameters (UAP/CAP) between iLivTouch-FT9000 and FibroScan 530 devices.
Secondary Objectives
1. To compare the operational features of the two devices, reflected in the success rate of examination and number of effective examinations.
2. To compare LSM obtained from each device with liver stiffness estimated by APRI, FIB-4, and SAFE scores.
3. The number of adverse events, serious events, and percentage of subjects with events will be calculated for AE, SAE, AE of special interest, and AE leading to study withdrawal.

Enrollment

418 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

a. Adults aged above 18 years old who have at least one indication for TE examination determined by the physicians;
b. Patients who have test results for platelet count, ALT, AST, globulin, HBA1c, and total bilirubin (TBIL) levels within 60 days;
c. Patients who are willing to participate in the clinical study and can sign ICF.

Exclusion criteria

a. Excessive drinking history within 90 days: For women-140 grams of alcohol per week or more; For men-210 grams of alcohol per week or more;
b. Patients with alanine aminotransferase (ALT) or aspartate aminotransferase AST >100 U/ml (or 2.5 × upper limit of normal (ULN) and/or total bilirubin (TBIL) > 1.8 mg/d (or >1.5 × ULN =1.2 mg/d);
c. Patients with a history or current evidence of decompensated liver cirrhosis;
d. Patients with various space-occupying tumors and cysts in the right liver;
e. Patients with other serious systemically diseases or a history of malignant tumors;
f. Patients with ascites;
g. Patients with a non-healing wound on the right upper abdomen at this moment;
h. Patients with intracavitary implantation of instruments;
i. Pregnant women (urine pregnancy test should be performed for all women with child-bearing potential during screening);
j. Any history of organ transplantation and existing functional grafts (except corneal or hair transplantation);
k. Lack of or limited legal capacity.